Summary
This Form 8-K filing by Thermo Fisher Scientific Inc. (TMO) on July 13, 2011, primarily reports two significant corporate governance changes. Firstly, Lars Rebien Sørensen, President and CEO of Novo Nordisk A/S, was elected to the company's Board of Directors, effective July 12, 2011. He has also been appointed to the Corporate Social Responsibility Committee, bringing valuable experience from a leading global healthcare company. Secondly, the company's Board of Directors approved amendments to its bylaws, effective July 12, 2011, to eliminate the classified board structure. This means the board will transition to all directors being elected annually, with the full transition for all directors to be up for annual election completed by the 2014 annual meeting. This move towards annual elections for all directors and the possibility of removal by stockholders represents a significant shift in corporate governance, potentially increasing accountability to shareholders.
Key Highlights
- 1Lars Rebien Sørensen, CEO of Novo Nordisk A/S, appointed to Thermo Fisher Scientific's Board of Directors.
- 2Mr. Sørensen also appointed to the Board's Corporate Social Responsibility Committee.
- 3Thermo Fisher Scientific's Board of Directors has voted to eliminate the classified board structure.
- 4The declassification of the board means all directors will be up for annual election.
- 5The transition to a fully declassified board will be completed by the 2014 annual meeting.
- 6Directors can now be removed by stockholders with or without cause.
- 7New directors elected after July 12, 2011, will serve terms expiring at the next annual stockholders' meeting.